Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Abbott labs | Mind Blowing Facts

This Boring Dividend King Might Be the Safest Pick to Add to Your Portfolio

Abbott Labs is a balance of income and growth.

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

S&P Futures Climb on Fed Rate-Cut Optimism, More Big Bank Earnings on Tap

S&P Futures Climb on Fed Rate-Cut Optimism, More Big Bank Earnings on Tap

December S&P 500 E-Mini futures (ESZ25) are trending up +0.63% this morning amid optimism over Federal Reserve interest-rate cuts following dovish comments from Fed Chair Jerome Powell, while investors await quarterly reports from more big banks.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Love Dividends? 2 Passive Income Stocks to Scoop Up Now.

These consistent dividend-paying stocks could be a good addition to your portfolio.

These Dividend Aristocrats Could Be a Slam Dunk in 2025

These companies offer stability and a history of dividend growth. Are they right for you?

S&P Futures Plunge as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap

December S&P 500 futures (ESZ23) are trending down -0.45% this morning as uncertainties lingered in the Middle East, and investors weighed the possibility of further rate hikes by the Federal Reserve while eagerly awaiting earnings results from U.S. heavyweights Tesla and Netflix.

S&P Futures Drop as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap

December S&P 500 futures (ESZ23) are trending down -0.34% this morning as uncertainties lingered in the Middle East, and investors weighed the possibility of further rate hikes by the Federal Reserve while eagerly awaiting earnings results from U.S. heavyweights Tesla and Netflix.

inkl

Read news from The Economist, FT, and more,
with one subscription

Nasdaq Futures Plunge as Disappointing Tesla and Netflix Results Weigh on Sentiment

Nasdaq Futures Plunge as Disappointing Tesla and Netflix Results Weigh on Sentiment

September Nasdaq 100 E-Mini futures (NQU23) are down -0.67% this morning as disappointing earnings results from U.S. heavyweights Tesla and Netflix weighed on sentiment, while investors looked ahead to the next round of corporate earnings.

Stock Index Futures Plunge on Pressure from Rising Bond Yields, Tesla Earnings on Tap

Stock Index Futures Plunge on Pressure from Rising Bond Yields, Tesla Earnings on Tap

June S&P 500 futures (ESM23) are down -0.46%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.76% this morning after three major U.S. benchmark indices struggled for direction on Tuesday as investors weighed the latest batch of earnings reports and comments from two Federal Reserve officials.

Stock Index Futures Slip as Bond Yields Climb, Tesla Earnings on Tap

Stock Index Futures Slip as Bond Yields Climb, Tesla Earnings on Tap

June S&P 500 futures (ESM23) are down -0.46%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.76% this morning after three major U.S. benchmark indices struggled for direction on Tuesday as investors weighed the latest batch of earnings reports and comments from two Federal Reserve officials.

Is Abbott Labs A "Strong Buy" After Earnings?

Is Abbott Labs A "Strong Buy" After Earnings?

Leading healthcare company Abbott Laboratories (ABT) reported strong second-quarter results. And given the company is well-positioned to capitalize on its diverse business and recent FDA approvals, is it wise to buy the stock now? Let’s find out.

The US baby formula shortage isn’t bad luck. It was completely preventable

The US baby formula shortage isn’t bad luck. It was completely preventable

Shortages of vital, life-preserving goods are routine in America – and they’re the product of bad policy

The Guardian - US

Baby formula makers tell Biden they knew shortages would be dire

WASHINGTON — President Joe Biden defended his administration’s response to a national baby formula shortage, saying he acted as soon he became aware of the crisis in April — even as manufacturers told him Wednesday they saw it coming months earlier.

Tribune News Service

1

People

Sebastien Lecornu

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

NVIDIA Corporation

Abbott Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

382,433 stories

140,716 stories

Washington D.C.

the Middle East

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play